High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations.

Irfan Jawed,Laleh Amiri-Kordestani,Margarita Velarde,Karen T. Adams,Sanjeeve Balasubramaniam,James C. Reynolds,Karel Pacak,Antonio Tito Fojo

High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations.

2011

Irfan Jawed
Laleh Amiri-Kordestani
Margarita Velarde
Karen T. Adams
Sanjeeve Balasubramaniam
James C. Reynolds
Karel Pacak
Antonio Tito Fojo

2526 Background: Pheochromocytomas and paragangliomas are rare tumors of the adrenals and paraganglia, respectively. As many as 30% of pts harbor a mutation in the VHL, RET, NF1, SDHB, SDHC, or SDH...

Keywords:

Paraganglioma
Pathology
SDHB
Malignant Pheochromocytoma
Protein subunit
Cancer research
Cyclophosphamide/vincristine
Diabetes mellitus
Dacarbazine
Pharmacology
Medicine
Succinate dehydrogenase
Endocrinology
in patient
Internal medicine
Mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations